Patents Assigned to Senju Pharmaceutical Co., Ltd.
-
Patent number: 9562231Abstract: A therapeutic agent for a corneal epithelial disorder, containing a miR-203 inhibitor; an agent for promoting proliferation of corneal epithelial cells, containing a miR-203 inhibitor; a liquid culture medium for use in the manufacture of a corneal epithelial sheet, containing a miR-203 inhibitor; and a method for producing a corneal epithelial sheet, including the step of culturing corneal epithelial cells using a liquid culture medium containing a miR-203 inhibitor. According to the present invention, a therapeutic agent for a corneal epithelial disorder, an agent for promoting proliferation of corneal epithelial cells, a liquid culture medium for use in the manufacture of a corneal epithelial sheet, a method for producing a corneal epithelial sheet, including the step of culturing corneal epithelial cells using the liquid culture medium, and a method for treating a corneal epithelial disorder can be provided.Type: GrantFiled: August 27, 2014Date of Patent: February 7, 2017Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Ayumi Nakagawa, Takeshi Nakajima, Mitsuyoshi Azuma
-
Publication number: 20170002318Abstract: The present invention provides a method of culturing corneal endothelial cells. More specifically, the present invention provides a composition for culturing or growing corneal endothelial cells, comprising at least one agent consisting of laminins and fragments thereof which express in corneal endothelial cells. Specifically, the present invention can comprise laminin 511 (alpha5 beta1 gamma1) and laminin 512 (alpha5 beta2 gamma 1). The present invention further provides a culture container for corneal endothelial cells, which is coated with the composition of the present invention. Furthermore, the present invention provides a method for culturing corneal endothelial cells comprising the step of using the composition or the container of the present invention to culture the corneal endothelial cells.Type: ApplicationFiled: November 26, 2014Publication date: January 5, 2017Applicants: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, THE DOSHISHA, SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko KOIZUMI, Naoki OKUMURA, Shigeru KINOSHITA, Friedrich E. KRUSE, Ursula SCHLOETZER-SCHREHARDT
-
Patent number: 9486362Abstract: The present invention aims to provide a ring-shaped device superior in the wearing comfort and intraocular stability while being worn on the eye. Provided is a ring-shaped device to be worn on the scleral surface, which is characterized in that it has an opening to expose the cornea and an intermediate portion between an inner edge portion and an outer edge portion has a maximum thickness.Type: GrantFiled: December 25, 2009Date of Patent: November 8, 2016Assignees: Senju Pharmaceutical Co., Ltd., SEED Co., Ltd.Inventors: Yuko Shikamura, Takao Sato, Toru Matsunaga, Yoshiko Yamazaki, Tsutomu Fukushima
-
Publication number: 20160317528Abstract: The present invention provides an agent for treating or preventing a disease, a disorder or a condition of a corneal endothelium, said agent comprising a corneal endothelial cell and a myosin II-specific inhibitor. More specifically, the myosin II-specific inhibitor is blebbistatin. The disease, the disorder or the condition is typically a disorder associated with Fuchs endothelial corneal dystrophy or corneal endothelial dysfunction (bullous keratopathy). Also provided is a method for treating or preventing a corneal endothelial disease, said method comprising a step of administering an effective amount of a myosin II-specific inhibitor together with a corneal endothelial cell to a subject.Type: ApplicationFiled: December 27, 2013Publication date: November 3, 2016Applicants: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, THE DOSHISHA, SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko KOIZUMI, Naoki OKUMURA, Shigeru KINOSHITA
-
Publication number: 20160296505Abstract: The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress. Specifically, the present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress in the corneal epithelium, the drug containing a TGF?-signal inhibitor. As a preferred TGF?-signal inhibitor, the drug contains 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide.Type: ApplicationFiled: October 30, 2014Publication date: October 13, 2016Applicants: Kyoto Prefectural Public University corporation, The Doshisha, Senju Pharmaceutical Co., Ltd.Inventors: Noriko KOIZUMI, Naoki OKUMURA, Shigeru KINOSHITA
-
Patent number: 9463185Abstract: A preparation containing [3-[2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid, [4-[3-[2-(4-trifluoromethyl)phenyl-4-isopropyl-5-thiazolyl]propionyl]-2-methylphenoxy]acetic acid or [4-[3-[2-(2-hydroxy-4-chlorophenyl)-5-isopropyl-4-oxazolyl]propionyl]-2-methylphenoxy]acetic acid, or a pharmacologically acceptable salt thereof as an active ingredient is used as an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, as well as a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like.Type: GrantFiled: June 27, 2014Date of Patent: October 11, 2016Assignees: SENJU PHARMACEUTICAL CO., LTD., NIPPON CHEMIPHAR CO., LTD.Inventors: Yoshikuni Nakamura, Ikuko Hanano, Jun Inoue
-
Publication number: 20160208250Abstract: A therapeutic agent for a corneal epithelial disorder, containing a miR-203 inhibitor; an agent for promoting proliferation of corneal epithelial cells, containing a miR-203 inhibitor; a liquid culture medium for use in the manufacture of a corneal epithelial sheet, containing a miR-203 inhibitor; and a method for producing a corneal epithelial sheet, including the step of culturing corneal epithelial cells using a liquid culture medium containing a miR-203 inhibitor. According to the present invention, a therapeutic agent for a corneal epithelial disorder, an agent for promoting proliferation of corneal epithelial cells, a liquid culture medium for use in the manufacture of a corneal epithelial sheet, a method for producing a corneal epithelial sheet, including the step of culturing corneal epithelial cells using the liquid culture medium, and a method for treating a corneal epithelial disorder can be provided.Type: ApplicationFiled: August 27, 2014Publication date: July 21, 2016Applicant: SENJU PHARMACEUTICAL CO., LTD.Inventors: Ayumi NAKAGAWA, Takeshi NAKAJIMA, Mitsuyoshi AZUMA
-
Publication number: 20160067181Abstract: The purpose of the present invention is to provide a technique for formulating a two-layer separation-type ophthalmic solution in which, during storage, an aqueous layer and an oil-containing layer containing squalane are separated from each other, wherein it is possible to homogeneously disperse the oil-containing layer in the aqueous layer while suppressing foaming by shaking the ophthalmic solution before administration, and the homogeneous dispersed state is maintained in a stable manner at least until administration. A two-layer separation-type ophthalmic solution containing squalane and water, wherein hyaluronic acid and/or a salt thereof and polyvinyl alcohol are contained in the ophthalmic solution and the polyvinyl alcohol content is set to 0.025 to 0.Type: ApplicationFiled: March 18, 2014Publication date: March 10, 2016Applicant: SENJU PHARMACEUTICAL CO., LTD.Inventor: Shirou SAWA
-
Patent number: 9248125Abstract: The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.Type: GrantFiled: August 28, 2008Date of Patent: February 2, 2016Assignees: Senju Pharmaceutical Co., Ltd.Inventors: Noriko Koizumi, Shigeru Kinoshita, Morio Ueno
-
Patent number: 9144609Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. An embodiment of said liquid preparation does not include any preservative. Said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).Type: GrantFiled: May 5, 2014Date of Patent: September 29, 2015Assignee: SENJU PHARMACEUTICAL CO., LTD.Inventors: Shirou Sawa, Shuhei Fujita, George A. Baklayan, Angeliqueo E. Padilla
-
Patent number: 9107888Abstract: An aqueous liquid bromfenac composition containing (a) bromfenac or a salt thereof and (b) benzalkonium chloride, characterized by that the composition has preservative efficacy and that the concentration of (b) benzalkonium chloride is higher than 0.0005% and lower than 0.005%.Type: GrantFiled: January 18, 2012Date of Patent: August 18, 2015Assignee: SENJU PHARMACEUTICAL CO., LTD.Inventors: Shuichi Nishihata, Wakiko Asayama, Suzuka Iemoto
-
Patent number: 9096538Abstract: An object of the present invention is to provide an agent for promoting proliferation of a meibomian gland epithelial cell and a corneal epithelial cell, as well as provide an agent for treating an ocular disease such as meibomian gland dysfunction or evaporative dry eye. There are provided an agent for promoting proliferation of a meibomian gland epithelial cell or a corneal epithelial cell, containing a PPAR? or ? agonist as an active ingredient, as well as an agent for treating an ocular disease such as meibomian gland dysfunction or evaporative dry eye, containing a PPAR? or ? agonist as an active ingredient.Type: GrantFiled: February 28, 2012Date of Patent: August 4, 2015Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Yoshikuni Nakamura, Ikuko Hanano, Jun Inoue
-
Publication number: 20150202256Abstract: The present invention relates to a differentiation marker and a differentiation controlling technique for an eye cell. More particularly, the present invention has attained an object of providing a differentiation marker for an eye cell among the aforementioned problems, by providing a marker for identifying a cell having a high proliferation ability among corneal endothelial cells and/or the differentiation ability of a corneal endothelial cell, the marker comprising GPR49/LGR5, as well as a detection agent or detection method for identifying a cell having a high proliferation ability among corneal endothelial cells and/or the differentiation ability of a corneal endothelial cell, comprising a substance binding to GPR49/LGR5. In addition, the present invention has attained an object of providing a differentiation controlling technique for an eye cell, by providing an agent for suppressing differentiation and/or promoting proliferation of an eye cell, comprising R-spondins.Type: ApplicationFiled: July 3, 2013Publication date: July 23, 2015Applicants: Kyoto Prefectural Public University Corporation, Senju Pharmaceutical Co., Ltd., The DoshishaInventors: Takahiro Nakamura, Noriko Koizumi, Naoki Okumura, Shigeru Kinoshita, Kana Tominaga, Satoshi Kawasaki
-
Publication number: 20150073459Abstract: Provided is a fragmentation tip, an intraocular surgery device, a method for suppressing an occurrence of cavitation, and a cataract surgery method, which can suppress the occurrence of cavitation. The fragmentation tip, which is attached to an intraocular surgery device configured to apply ultrasonic vibration, includes: a cylindrical support portion configured to be mounted on the intraocular surgery device; and a cylindrical tip body provided at a distal end of the support portion to be in communication with an internal space of the support portion, wherein the tip body has a cross sectional shape having a length in a first direction that is larger than a length in a second direction that is orthogonal to the first direction, and vibration is applied to the support portion so that the tip body rotates back and forth about an axis of the tip body that passes through its center in the first and second directions.Type: ApplicationFiled: April 18, 2012Publication date: March 12, 2015Applicant: SENJU PHARMACEUTICAL CO., LTD.Inventor: Makoto Kishimoto
-
Publication number: 20150044178Abstract: The present invention provides a method for the normalized culturing of corneal endothelial cells. More specifically, the present invention provides a culture-normalizing-agent of a corneal endothelial cell, comprising a fibrosis inhibitor. In detail, the present invention provides a culture-normalizing agent comprising a transforming growth factor (TGF) ? signal inhibitor. The present invention also provides a culture medium for culturing a corneal endothelial cell normally, which comprises the culture-normalizing agent according to the present invention and corneal endothelium culture components. The present invention also provides a method for culturing a corneal endothelial cell normally, comprising the step of culturing a corneal endothelial cell using the culture-normalizing agent according to the present invention or the culture medium according to the present invention.Type: ApplicationFiled: December 27, 2012Publication date: February 12, 2015Applicants: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, SENJU PHARMACEUTICAL CO., LTD., THE DOSHISHAInventors: Shigeru Kinoshita, Noriko Koizumi, Naoki Okumura
-
Patent number: 8940318Abstract: Disclosed is a sustainedly drug-releasing hydrogel contact lens which can sustainedly release an anionic medicament such as an allergy-treating agent in a mildly irritating and effective manner while achieving vision correction. Specifically disclosed is a hydrogel comprising ionic monomers composed of at least a cationic monomer and an anionic monomer, wherein the component ratio of the ionic monomers is 5 to 20 mol % inclusive relative to the total amount of monomers that constitute the gel, and the content of the anionic monomer is 15 to 25 mol % inclusive relative to the content of the cationic monomer.Type: GrantFiled: January 15, 2010Date of Patent: January 27, 2015Assignees: Seed Co., Ltd., Senju Pharmaceutical Co., Ltd.Inventors: Takao Sato, Toru Matsunaga, Aya Ichinokawa, Osamu Sakai
-
Patent number: 8927606Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).Type: GrantFiled: September 23, 2014Date of Patent: January 6, 2015Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Shirou Sawa, Shuhei Fujita
-
Patent number: 8895508Abstract: The present invention aims to provide a corneal endothelium cell proliferation accelerator and a therapeutic agent for a disease relating to corneal endothelium damage, which are administered into the anterior chamber. bFGF is released in a sustained manner by forming bFGF sustained-release gelatin hydrogel particles wherein bFGF is carried on gelatin hydrogel. Therefore, the proliferation of corneal endothelium cells can be accelerated persistently by administration of a preparation containing the bFGF sustained-release gelatin hydrogel particles into the anterior chamber, and diseases relating to corneal endothelium damage can be treated.Type: GrantFiled: July 24, 2009Date of Patent: November 25, 2014Assignees: Senju Pharmaceutical Co., Ltd.Inventors: Yasuhiko Tabata, Shigeru Kinoshita, Noriko Koizumi, Yuji Sakamoto, Naoki Okumura, Hiroaki Takahashi
-
Patent number: 8883825Abstract: An aqueous liquid preparation containing (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid or a pharmacologically acceptable acid addition salt thereof, which is stabilized with a water-soluble metal chloride, is provided.Type: GrantFiled: August 30, 2012Date of Patent: November 11, 2014Assignee: Senju Pharmaceutical Co., Ltd.Inventor: Masayo Higashiyama
-
Patent number: 8877168Abstract: An aqueous liquid preparation containing (+)-(S)-4-[4-[(4-chlorophenyl) (2-pyridyl)methoxy]piperidino]butyric acid or a pharmacologically acceptable acid addition salt thereof, which is stabilized with a water-soluble metal chloride, is provided.Type: GrantFiled: June 25, 2014Date of Patent: November 4, 2014Assignee: Senju Pharmaceuticals Co., Ltd.Inventor: Masayo Higashiyama